Alvotech’s Simponi Biosimilar Steps Into Phase III RA Study

‘ALVOFLEX’ Trial Follows Recent Phase I PK Study For AVT05 Candidate

 
• By Dean Rudge
  
Robert Wessman Alvogen Alvotech
Robert Wessman became Alvotech CEO in January • Source: Alvotech
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products